While preclinical data is promising, its important to recognize that neither peptide is FDA-approved for human therapeutic use, and most evidence is derived from animal or laboratory studies
Zvintzou E, Skroubis G, Chroni A, Petropoulou PI, Gkolfinopoulou C, Sakellaropoulos G, et al
Individuals interested in speeding their recovery from injury or surgery should consider Thymosin Beta
Products are for qualified researchers in academic, pharmaceutical or biotechnology settings with appropriate training and facilities
Choose injectable BPC-157 if: Your target is a tendon, ligament, joint, or muscle injury You need systemic anti-inflammatory or tissue repair effects Speed and reliability of delivery matter You are working within a structured peptide therapy protocol with a licensed provider Choose oral BPC-157 if: Your primary concern is gut health leaky gut, IBD, IBS, gastric ulcers You want high local GI concentrations, not systemic distribution You prefer non-invasive administration for long-term or maintenance use You are combining BPC-157 with another systemic peptide therapy Consider nasal delivery only if: Neurological applications are the clinical focus A licensed provider explicitly recommends it based on your presentation Injection is contraindicated and oral delivery is insufficient Do not choose a delivery method based on convenience alone
